Circumcision linked to reduced risk of prostate cancer in some men

May 29, 2014

Circumcision is performed for various reasons, including those that are based on religion, aesthetics, or health. New research indicates that the procedure may help prevent prostate cancer in some men. The findings, which are published in BJU International, add to a growing list of advantages to circumcision.

Besides advanced age, African ancestry, and family history of prostate cancer, no other risk factors for prostate cancer have been definitively established. This has fuelled the search for modifiable risk factors. Marie-Élise Parent, PhD and Andrea Spence, PhD, of the University of Quebec's INRS-Institut Armand-Frappier, led a team that designed an observational study to investigate the possible association between circumcision and prostate cancer risk. Their study, called PROtEuS (Prostate Cancer and Environment Study), included 1590 prostate cancer patients diagnosed in a Montréal hospital between 2005 and 2009, as well as 1618 healthy control individuals. In-person interviews were conducted to gather information on sociodemographic, lifestyle, and environmental factors.

Circumcised men had a slightly lower risk, albeit not statistically significant, of developing prostate cancer than uncircumcised men. Circumcision was found to be protective in men circumcised when they were older than 35 years, with the procedure decreasing their risk by 45%. A weaker protective effect was seen among men circumcised within 1 year of birth, with the procedure decreasing their risk by 14%. The strongest protective effect of circumcision was recorded in Black men, who had a 60% reduced risk if they were circumcised, but no association was found with other ancestral groups. "This is a particularly interesting finding, as Black men have the highest rates of prostate cancer in the world and this has never been explained," said Dr. Parent. "This novel finding warrants further examination in future studies that have a larger number of Black participants."

Dr. Parent noted that circumcision may reduce the risk of contracting and maintaining a sexually transmitted infection, which has been postulated to be a risk factor for prostate cancer. This may explain the reduced risk of prostate cancer observed in males circumcised at a younger age prior to any potential exposure to infection. "We do not know why a protective effect was observed for men circumcised after the age of 35. These men may have had a pathologic condition of the foreskin that lead to them being circumcised," she said.

Another study related to circumcision published in BJU International addresses the issue of HIV infection and circumcision. Previous studies have found that circumcision reduces a man's risk of becoming infected with HIV by 50% to 60%, and the procedure has the potential to reduce the HIV epidemic in areas of Eastern and Southern Africa where circumcision is uncommon and the epidemic most severe. As circumcision is promoted in these regions, HIV-positive men will likely seek the procedure either because they do not know their HIV status or to avoid being stigmatized. If post-surgical complications arise and intercourse is resumed before wound healing is complete, there may be an increased risk of HIV transmission to female partners. In this latest study, investigators in Uganda and the United States found that HIV infection does not significantly impair healing of circumcision wounds; therefore, HIV-positive men should not be denied the service if they request it.
-end-
The study was supported financially through grants from the Canadian Cancer Society, the Cancer Research Society, the Fonds de la recherche du Québec--Santé (FRQS), FRQS-RRSE, the Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec, and the Canadian Institutes for Health Research.

Wiley

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.